Consensus Ultragenyx Pharmaceutical Inc.

Stocks

RARE

US90400D1081

Pharmaceuticals

Market Closed - Nasdaq 16:00:00 2026-08-31 EDT			5-day change	1st Jan Change
25.21 ^USD	-1.56%		-1.98%	+9.61%

08-20	Ultragenyx Pharmaceutical Inc. - Special Call
08-19	Ultragenyx Pharmaceutical Receives Accelerated US FDA Approval for Genglycos	MT

Evolution of the Average Target: Ultragenyx Pharmaceutical Inc.

Evolution of the Target Price: Ultragenyx Pharmaceutical Inc.

Changes in Analyst Recommendations: Ultragenyx Pharmaceutical Inc.

c7ecc56.hm2EEKoOezQAuuqZYQQCaEVYWXP0OJW3Pp0Ib6gicNQ.5TLVc5o4NwZ2_LLvEW17KnABaRumXa3lcdg-ON9XE5_2CsNC43xJXGTtnQ~90ff107e6b4b23924aa1692ed9a976c2

Analysts' recommendations: Ultragenyx Pharmaceutical Inc.

07-13	Wedbush Raises Price Target on Ultragenyx Pharmaceutical to $30 From $26, Keeps Neutral Rating	MT
07-07	RBC Capital Adjusts Ultragenyx Pharmaceutical Price Target to $40 From $35, Maintains Outperform Rating	MT
05-06	Wedbush Trims Price Target on Ultragenyx Pharmaceutical to $26 From $27, Maintains Neutral Rating	MT
04-21	Wedbush Lifts Price Target on Ultragenyx Pharmaceutical to $27 From $25, Keeps Neutral Rating	MT
03-24	Goldman Sachs Downgrades Ultragenyx Pharmaceutical to Neutral From Buy, Adjusts PT to $25 From $61	MT
02-13	Truist Cuts Price Target on Ultragenyx Pharmaceutical to $76 From $90, Keeps Buy Rating	MT
01-23	Wedbush Raises Price Target on Ultragenyx Pharmaceutical to $25 From $23, Keeps Neutral Rating	MT
01-08	RBC Cuts Price Target on Ultragenyx Pharmaceutical to $35 From $72, Keeps Outperform, Speculative Risk	MT
12-29	Barclays Cuts Price Target on Ultragenyx Pharmaceutical to $44 From $50, Keeps Overweight Rating	MT
12-29	Wedbush Adjusts Price Target on Ultragenyx Pharmaceutical to $23 From $35, Maintains Neutral Rating	MT
11-05	RBC Capital Adjusts Ultragenyx Pharmaceutical Price Target to $72 From $77, Maintains Outperform Rating	MT
25-10-22	BofA Securities Adjusts Ultragenyx Pharmaceutical Price Target to $74 From $79, Maintains Buy Rating	MT
25-10-14	Wedbush Lifts Price Target on Ultragenyx Pharmaceutical to $35 From $34, Keeps Neutral Rating	MT
25-08-05	Ultragenyx Q2 revenue rises 13%	RE
25-07-14	Ultragenyx Outlook Dims After Setrusumab Trial Miss, UX111 FDA Setback, Morgan Stanley Says	MT
25-07-14	Wedbush Trims Price Target on Ultragenyx Pharmaceutical to $34 From $35, Keeps Neutral Rating	MT
25-07-14	Morgan Stanley Cuts Price Target on Ultragenyx Pharmaceutical to $55 From $65, Keeps Overweight Rating	MT
25-07-10	Wedbush Lowers Price Target on Ultragenyx Pharmaceutical to $35 From $39, Keeps Neutral Rating	MT
25-05-28	William Blair Initiates Ultragenyx Pharmaceutical at Outperform	MT
25-04-17	BofA Adjusts Price Target on Ultragenyx Pharmaceutical to $80 From $83, Keeps Buy Rating	MT
25-01-23	Wedbush Trims Price Target on Ultragenyx Pharmaceutical to $47 From $48, Keeps Neutral Rating	MT
24-08-02	Wedbush Adjusts Ultragenyx Pharmaceutical's PT to $46 From $43, Keeps Neutral Rating	MT
24-06-14	Wedbush Adjusts Ultragenyx Pharmaceutical's Price Target to $45 From $48, Keeps Neutral Rating	MT
24-06-06	Goldman Sachs Upgrades Ultragenyx Pharmaceutical to Buy From Neutral, Raises Price Target to $67 From $56	MT
24-05-31	Cantor Fitzgerald Adjusts Price Target on Ultragenyx Pharmaceutical to $115 From $107, Maintains Overweight Rating	MT